As FDA's Peter Marks resigns, industry watchers size up vaccine, cell and gene therapy hits
As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency is heading for the exit. | In resigning as director of the FDA’s Center for Biologics Evaluation and Research,
Follow the Science: Why Peter Marks Was Asked to Leave the FDA
Dr. Peter Marks announced his resignation from the U.S. Food and Drug Administration (FDA) as Director of CEBR (Center for Biologics Evaluation and Research) citing differences with Health and Human Services (HHS) Secretary Kennedy regarding vaccines.
The pharma industry, Wall Street and former government officials on Monday decried the forced resignation of FDA vaccine ...
It's not yet been a week since Marty Makary, M.D., was confirmed to lead the FDA as its commissioner. | Peter Marks, M.D., Ph ...
Marks offered his resignation while citing Kennedy’s “misinformation and lies” and an “unprecedented assault on scientific ...
Commissioner Marty Makary signed off on the plan to push out the agency’s top vaccine official, Peter Marks, in one of his ...
Steele, who joined the FDA in 2022, was previously senior adviser at the Center for Biologics Evaluation and Research, which regulates biological and related products including blood, vaccines, ...
Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary ...
10hon MSN
The departure comes just days after the FDA’s top vaccine official stepped down over disagreements with health secretary ...
The pharma and biotech sector has been under pressure since Donald Trump returned to the White House earlier this year.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback